Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics


Mirati Therapeutics, Inc. (MRTX)

Today's Latest Price: $103.00 USD

1.02 (-0.98%)

Updated May 28 8:00pm

Add MRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

MRTX Stock Summary

  • The ratio of debt to operating expenses for Mirati Therapeutics Inc is higher than it is for about merely 0.34% of US stocks.
  • With a price/sales ratio of 1,925.23, Mirati Therapeutics Inc has a higher such ratio than 99.64% of stocks in our set.
  • As for revenue growth, note that MRTX's revenue has grown -49.86% over the past 12 months; that beats the revenue growth of only 3.61% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mirati Therapeutics Inc are NYMX, TOCA, SCYX, ITCI, and MRSN.
  • MRTX's SEC filings can be seen here. And to visit Mirati Therapeutics Inc's official web site, go to www.mirati.com.
MRTX Daily Price Range
MRTX 52-Week Price Range

MRTX Stock Price Chart More Charts


MRTX Price/Volume Stats

Current price $103.00 52-week high $132.59
Prev. close $104.02 52-week low $66.01
Day low $102.53 Volume 271,600
Day high $105.40 Avg. volume 584,471
50-day MA $88.36 Dividend yield N/A
200-day MA $91.69 Market Cap 4.50B

Mirati Therapeutics, Inc. (MRTX) Company Bio


Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.


MRTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

MRTX Latest Social Stream


Loading social stream, please wait...

View Full MRTX Social Stream

Latest MRTX News From Around the Web

Below are the latest news stories about Mirati Therapeutics Inc that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020. Isan Chen, M.D., will step down as Chief Medical and…

PR Newswire | May 18, 2020

Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

SAN DIEGO, May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cancer…

PR Newswire | May 15, 2020

Mirati Dives As Short Seller Says Key Pipeline Assets Doomed

Mirati Therapeutics Inc (NASDAQ: MRTX ) shares were seeing weakness Tuesday after short seller Kerrisdale Capital released a bleak report concerning its two investigational assets. Mirati's lead cancer drug candidate sitravatinib, a multi-kinase inhibitor, has not lived up to its promise, according to Kerrisdale. All of its prospects for single-agent potential have evaporated, and the combo studies looking like more of a diversion attempt rather than a legitimate therapeutic candidate with a scientific rationale, the short seller said in the report. It was the promise held out by sitravatinib that propelled Mirati to become a $1-billion biotech, according to Kerrisdale. Kerrisdale said this leaves Mirati relying on its KRAS … Full story available on Benzinga.com

Benzinga | April 21, 2020

Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates

SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31, 2019. "In 2019, we advanced MRTX849, our KRAS G12C inhibitor into a Phase…

PR Newswire | February 25, 2020

Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium

SAN DIEGO, Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab…

PR Newswire | February 15, 2020

Read More 'MRTX' Stories Here

MRTX Price Returns

1-mo 17.31%
3-mo 15.10%
6-mo 2.21%
1-year 47.33%
3-year 3,222.58%
5-year 180.96%
YTD -20.07%
2019 203.77%
2018 132.44%
2017 284.21%
2016 -84.97%
2015 70.63%

Continue Researching MRTX

Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:

Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0365 seconds.